Advair sales strategy shifting in 2007

Share this article:
GlaxoSmithKline is shifting its sales force strategy for therapy Advair to stress treatment for chronic obstructive pulmonary disease (COPD), a new report stated.

Advair, a long-acting beta2 agonist combined with an inhaled corticosteroid is GSK's best-selling drug.

About 58% of its 2005 sales came from the asthma market, with 42% coming from COPD, according to the report from Decision Resources and Millennium Research Group.

Advair sales for COPD grew three times the rate of asthma sales from 2003 to 2005, the report noted.

GSK's David Stout, president, pharmaceuticals, announced the formation of a dedicated COPD sales force in presentation to investors in late 2006. The sales force was created after the submission of data to US and European regulators showing reduced mortality in patients with COPD who were treated with Advair.

A focus on the benefits of Advair in COPD by the new sales force will enable existing reps to focus on asthma.

“If nothing else,” the report states, “the increased promotional efforts…will help to maintain a significant share of voice for the drug in the face of what are sure to be extensive promotional activities conducted by AstraZeneca in support of the US launch of Symbicort” in 2007.
Symbicort was approved by the FDA in July for maintenance treatment of asthma. 

A number of other lower-priced combination products will compete with Advair in coming years, causing sales to slide by $1 billion by 2010, researchers noted. Advair had 2005 US sales of $4.4 billion. Yet GSK will maintain its market-leading position, researchers said. The product is available as Advair Diskus DPI and in the Advair HFA formulation approved in 2006.

The No. 2 and No. 3 competitors in the asthma market in 2005, Merck and AstraZeneca respectively, will maintain their positions through 2010, the report states. Sales of Merck's Singulair will be flat due to market saturation and AstraZeneca will stay mired in third place, since added revenue from the US launch of Symbicort will be largely offset by declining sales of Pulmicort due to continued generic erosion in Europe and other factors.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...